Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Female Sexual Dysfunction - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2017, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape. Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 8, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health). - The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Female Sexual Dysfunction - Overview Female Sexual Dysfunction - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Female Sexual Dysfunction - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Female Sexual Dysfunction - Companies Involved in Therapeutics Development Allergan Plc Emotional Brain BV Fabre-Kramer Pharmaceuticals Inc GlaxoSmithKline Plc M et P Pharma AG M Pharmaceutical Inc Palatin Technologies Inc Re-Pharm Ltd Strategic Science & Technologies LLC TherapeuticsMD Inc Valeant Pharmaceuticals International Inc Female Sexual Dysfunction - Drug Profiles (buspirone hydrochloride + testosterone) - Drug Profile Product Description Mechanism Of Action R&D Progress (sildenafil citrate + testosterone) - Drug Profile Product Description Mechanism Of Action R&D Progress AB-101 - Drug Profile Product Description Mechanism Of Action R&D Progress BP-101 - Drug Profile Product Description Mechanism Of Action R&D Progress bremelanotide - Drug Profile Product Description Mechanism Of Action R&D Progress estradiol acetate - Drug Profile Product Description Mechanism Of Action R&D Progress Extrinsa - Drug Profile Product Description Mechanism Of Action R&D Progress FKW-00GA - Drug Profile Product Description Mechanism Of Action R&D Progress gepirone hydrochloride ER - Drug Profile Product Description Mechanism Of Action R&D Progress S1B-3006 - Drug Profile Product Description Mechanism Of Action R&D Progress S1B-307 - Drug Profile Product Description Mechanism Of Action R&D Progress sildenafil citrate - Drug Profile Product Description Mechanism Of Action R&D Progress SIP-104 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Sexual Dysfunction - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile Product Description Mechanism Of Action R&D Progress SPT-201 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile Product Description Mechanism Of Action R&D Progress TBS-2 - Drug Profile Product Description Mechanism Of Action R&D Progress WC-3011 - Drug Profile Product Description Mechanism Of Action R&D Progress Female Sexual Dysfunction - Dormant Projects Female Sexual Dysfunction - Discontinued Products Female Sexual Dysfunction - Product Development Milestones Featured News & Press Releases Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference Oct 28, 2015: Strategic Science and Technologies Initiates Phase 2 Study to Evaluate Topical Sildenafil in Women with Female Sexual Arousal Disorder Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Female Sexual Dysfunction, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Female Sexual Dysfunction - Pipeline by Allergan Plc, H1 2017 Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2017 Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017 Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H1 2017 Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2017 Female Sexual Dysfunction - Pipeline by M Pharmaceutical Inc, H1 2017 Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H1 2017 Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2017 Female Sexual Dysfunction - Pipeline by Strategic Science & Technologies LLC, H1 2017 Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2017 Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017 Female Sexual Dysfunction - Dormant Projects, H1 2017 Female Sexual Dysfunction - Dormant Projects, H1 2017 (Contd..1), H1 2017 Female Sexual Dysfunction - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
